Roth Reaffirms Peregrine Pharma (PPHM) at Buy; Prelim. Bavituximab + Sorafenib Phase I/II is Positive
Get Alerts PPHM Hot Sheet
Price: $0.61 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Roth Capital affirms its Buy rating on Peregrine Pharmaceuticals (Nasdaq: PPHM) following an update on the ongoing Phase I/II IST of bavituximab in combination with sorafenib in liver cancer.
Analyst Joseph Pantginis said,
What's the analysis?
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Peregrine Pharmaceuticals closed at $2.23 yesterday, with a 52 week range of $1.11 - $2.43.
Analyst Joseph Pantginis said,
We see this preliminary Phase I data as a positive for PPHM as the trial moves into Phase II. The Phase I data support dosing Phase II patients at the 3.0 mg/kg dose, which is the highest of the Phase I doses. The Phase I data also demonstrate that the combination led only to toxicities common to sorafenib and that no dose limiting toxicities were seen. The Phase II has enrolled 34 out of 38 patients and is a single-arm open-label trial with a primary endpoint of radiologic time to progression and with secondary endpoints of OS and PFS. Treatment has begun in 10 patients, with the longest patient on treatment for 18 months already.
What's the analysis?
With Peregrine being a pivotal stage company, we view the risk/reward profile as favorable, and we believe visibility from the broadening bavi profile and partnering potential should drive the stock in 2014,Pantginis stated.
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Peregrine Pharmaceuticals closed at $2.23 yesterday, with a 52 week range of $1.11 - $2.43.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
- Walt Disney (DIS) PT Raised to $145 at Needham
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!